Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Company Overview - Oculis is a global biopharmaceutical company focused on saving sight and improving eye care [3] - The company has a differentiated pipeline with multiple innovative product candidates, including OCS-01 for diabetic macular edema and post-cataract surgery inflammation, licaminlimab (OCS-02) for dry eye disease and non-infectious anterior uveitis, and OCS-05 for acute optic neuritis [3] - Oculis is headquartered in Switzerland and operates in the U.S. and Iceland, aiming to enhance the health and quality of life for patients globally [3] Management and Events - Riad Sherif, M.D., the CEO of Oculis, will participate in a panel discussion on "Derisked Late-stage Candidates for Retinal Disorders" on August 15, 2024 [2] - A virtual company presentation will also be available on-demand on the same date [2] - Oculis management will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference [4]